ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,505.00
0.00%
US Tech 100
19,205.56
1.03%
Dow Jones
40,287.53
0.00%
Brent Oil
81.325
-1.16%
Bitcoin
67,610.84
-0.80%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Boundless Bio Inc (BOLD) Quote

Boundless Bio Inc

Boundless Bio Inc (BOLD)

21Shares AG
21Shares AG
3.56
-0.32
(-8.25%)
Closed July 19 4:00PM
Delayed by 15 minutes
3.39
-0.17
( -4.78% )
Pre Market: 8:12AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
3.39
Bid
1.43
Ask
4.00
Volume
260
0.00 Day's Range 0.00
3.44 52 Week Range 15.20
Market Cap
79.226M
Previous Close
3.56
Open
-
Last Trade
100
@
3.39
(formt)
Last Trade Time
08:12:00
Financial Volume
-
VWAP
-
Average Volume (3m)
98,698
Shares Outstanding
22,254,537
Dividend Yield
-
PE Ratio
-1.60
Earnings Per Share (EPS)
-2.22
Revenue
-
Net Profit
-49.43M

About Boundless Bio Inc

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical t... Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.boundlessbio.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Boundless Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BOLD. The last closing price for Boundless Bio was $3.56. Over the last year, Boundless Bio shares have traded in a share price range of $ 3.44 to $ 15.20.

Boundless Bio currently has 22,254,537 shares outstanding. The market capitalization of Boundless Bio is $79.23 million. Boundless Bio has a price to earnings ratio (PE ratio) of -1.60.

BOLD Latest News

More News

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable...

June 05 2024
Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 13 2024
Edgar (US Regulatory)

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

BBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR oncogene amplifications First patient dosed in Phase 1/2...

May 13 2024
Business Wire

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable...

May 06 2024
Business Wire

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

STARMAP (Study Treating Acquired Resistance: MAPK Amplifications) is a first-in-human, 3-part, Phase 1/2 study of BBI-825 as a single agent and in combination with select targeted cancer...

April 11 2024
Business Wire

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development, as a differentiated treatment approach for...

April 08 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.72-17.51824817524.114.493.44570053.99517607CS
4-1.34-28.32980972524.735.87993.44790244.34884825CS
12-8.55-71.60804020111.9412.263.44986987.44500525CS
26-10.86-76.210526315814.2515.23.441355319.84650808CS
52-10.86-76.210526315814.2515.23.441355319.84650808CS
156-10.86-76.210526315814.2515.23.441355319.84650808CS
260-34.9-91.1465134538.29603.4457635146.00269918CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 11.00
(45.70%)
22.47M
NCPLNetcapital Inc
$ 0.1405
(35.10%)
34.06M
RRRichtech Robotics Inc
$ 1.9393
(31.93%)
12.4M
MIRAMIRA Pharmaceuticals Inc
$ 0.8799
(27.74%)
757.05k
HEPAHepion Pharmaceuticals Inc
$ 1.29
(26.47%)
3.63M
HUBCWHub Cyber Security Ltd
$ 0.0121
(-47.39%)
1.67k
XCURExicure Inc
$ 0.3922
(-26.71%)
342.7k
SNTGSentage Holdings Inc
$ 2.05
(-17.34%)
26.62k
PIRSPieris Pharmaceuticals Inc
$ 6.00
(-17.24%)
9
BCBPBCB Bancorp Inc
$ 10.20
(-16.53%)
126
NCPLNetcapital Inc
$ 0.1405
(35.10%)
34.06M
SERVServe Robotics Inc
$ 11.00
(45.70%)
22.47M
RRRichtech Robotics Inc
$ 1.9393
(31.93%)
12.4M
MAXNMaxeon Solar Technologies Ltd
$ 0.2264
(5.01%)
7.54M
SQQQProShares UltraPro Short QQQ
$ 8.22
(-2.84%)
5.05M

Discussion

View Full Feed
georgie18 georgie18 1 minute ago
TELL...941...HOUSTON--(BUSINESS WIRE)--Woodside has entered into a definitive agreement to acquire all issued and outstanding common stock of Tellurian (NYSE: TELL) including its owned and operated US Gulf Coast Driftwood LNG development opportunity (“Driftwood LNG”).

“Through this ac
rosemountbomber rosemountbomber 2 minutes ago
I guess what is confusing is that when Amarin announced the reimbursement decision from Sweden, they also said this:

“. The Swedish decision follows the individual reimbursement in Denmark in mid-February of 2022 and marks a significant milestone for Amarin in Europe.”

AMRN
WooptdooU WooptdooU 2 minutes ago
Benny Hill slap Baldheaded lebby while he chases titsy around the bod room, hahaha...
LWLG
georgie18 georgie18 2 minutes ago
TELL...941...HOUSTON--(BUSINESS WIRE)--Woodside has entered into a definitive agreement to acquire all issued and outstanding common stock of Tellurian (NYSE: TELL) including its owned and operated US Gulf Coast Driftwood LNG development opportunity (“Driftwood LNG”).

“Through this ac
varjim varjim 2 minutes ago
https://seekingalpha.com/pr/19791992-arras-minerals-initiates-heli-temgeophysical-survey-of-maisor-and-aktasty-mineral-licenses
ARRKF
RealDutch RealDutch 3 minutes ago
How is RD discussing financial matters?

I'm not :-)

He is getting emotional again and overreacting. Happens frequently. But I am right on the money with this (pun intended).
ITUP
palaypu0406 palaypu0406 3 minutes ago
Please do but I did receive an mail that he is first wanting his outstanding dues be paid --
To our legal sense, we owe no past money as that engagement was to be onboarded with upfront performance delivery.
I do understand there was a communication gap on this front -- we thought in
ITUP
glenn1919 glenn1919 4 minutes ago
VVPR.......NCPL.........PSNY...................https://www.stockscores.com/charts/charts/?ticker=VVPR
https://www.stockscores.com/charts/charts/?ticker=NCPL
https://www.stockscores.com/charts/charts/?ticker=PSNY
NCPL PSNY VVPR
al44 al44 4 minutes ago
Exit Stage Far-Left: The Biden Aftermath

A whole heap of logistical and political problems and no clear answers.

by Mark Angelides | Jul 22, 2024


President Joe Biden on Sunday, July 21, officially pulled out of the 2024 race, leaving a slew of is
Awl416 Awl416 4 minutes ago
MEI Pharma to Consider Strategic Alternatives
MEIP
bucks2pennies bucks2pennies 5 minutes ago
I don't read into the 500k activity. To me, just a perfunctory effort by MMs to maintain ticker activity. Everybody is waiting for the inevitable turn of events for GTCH. Not understanding WHY it is taking GTCH so long to "sell" has gone beyond my imagination in actually providing the necessary a
GTCH
moola26 moola26 5 minutes ago
Bwhahahahha. Oh the lies….

Majority holding strong$$
PEACHMAN PEACHMAN 6 minutes ago
The decision to buy IFUS shares today around .093 is very simple.

If you believe paid bashers that IFUS is a scam and has no products,no science, no future,and just printing shares, than you also must believe that all the testing done in the next 6 months and beyond will scientifical
IFUS
Ckwilas83 Ckwilas83 6 minutes ago
Thank you! I just sent an email of dissent to both the investor and info alias.
UCPA
oilin07 oilin07 6 minutes ago
Agree
BLLB
PonkenPlonken PonkenPlonken 7 minutes ago
MLGO 2.91 one to watch off a bottom, some PM hits
MLGO
quester614 quester614 7 minutes ago
Doesn't matter because UNLESS they move the CASE to MA. NY courts have NO jurisdiction because of the Jurisdiction clause as CONFIRMED in my prior cite by COPILOT

https://investorshub.advfn.com/uimage/uploads/2024/7/22/m%5BygpScreenshot_2024-07-22_8.28.49_AM.png
XERI
n4807g n4807g 7 minutes ago
Another gimmick....Tesla to have humanoid robots for internal use next year, Musk says
https://finance.yahoo.com/news/tesla-humanoid-robots-internal-next-102629128.html

The implication here; Optimus will work along side humans, and be as capable. No doubt there will actually b
glenn1919 glenn1919 7 minutes ago
RR......TKNO......SERV........https://www.stockscores.com/charts/charts/?ticker=RR
https://www.stockscores.com/charts/charts/?ticker=TKNO
https://www.stockscores.com/charts/charts/?ticker=SERV
SERV TKNO
Myth Myth 7 minutes ago
Welcome to the Crossroads Board fuzzy !
georgie18 georgie18 7 minutes ago
CNTM...$1.77...https://schrts.co/uZJrcjjr ...Dip being accumulated on this extremely oversold Chart...🥳3 Million range Float...

MARLBOROUGH, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- ConnectM Technology Solutions, Inc. (Nasdaq: CNTM) (“ConnectM” or the “Company”), a technology
georgie18 georgie18 8 minutes ago
Good Morning...🥳...
WooptdooU WooptdooU 8 minutes ago
Grifters' Dilution Solution is lebby and the marcinobodi's way...this is the "in their pocket" bod's fault,,,,
LWLG
georgie18 georgie18 8 minutes ago
CNTM...$1.77...https://schrts.co/uZJrcjjr ...Dip being accumulated on this extremely oversold Chart...🥳3 Million range Float...

MARLBOROUGH, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- ConnectM Technology Solutions, Inc. (Nasdaq: CNTM) (“ConnectM” or the “Company”), a technology

Your Recent History

NASDAQ
BOLD
Boundless Bio
NASDAQ
BRLI
Brilliant Axquisition
LSE
GLO
Contourglobal
USOTC
PTOI
Plastic2Oil (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved